A lot of good information in this article. It discusses the significance of a Beth Israel endorsement. It discusses cost per treatment and the number aortic stenosis reimbursements per year by the US Medicare system.We can look at cost-per-scan against market penetration expectations. Still a lot of assumptions regarding growth so any numbers thrown around need to taken with a grain of salt. But keep in mind, as is discussed in the article, there are other indications echo solv is looking to break into. Some with much larger markets.
I was originally going to sell after revenue is generated. I'm actually keen to hold much longer than that.
https://**promotion blocked**/health/dr-borehams-crucible-can-this-aortic-stenosis-detection-specialist-keep-things-pumping-post-fda-approval/
"Reimbursement is expected to be around US$60 to US$64 per test, with Echo IQ taking a 24% cut and the hospitals pocketing the rest.Currently, the US Medicare system (for the over 65-year-olds) reimburses five million aortic stenosis images annually."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $151.6M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.3¢ | $104.1K | 443.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 359644 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 110557 | 7 |
View Market Depth
| Last trade - 11.34am 28/07/2025 (20 minute delay) ? |
| EIQ (ASX) Chart |